CD8A and neoplasm: STING agonists counteract this process by reprogramming TAMs toward an M1-like phenotype, characterized by upregulation of proinflammatory genes and downregulation of M2-associated transcripts, while simultaneously normalizing tumor vasculature through enhanced pericyte coverage and increased adhesion molecule expression, thereby promoting CD8+ T cell infiltration [57].